← 返回

新辅助治疗对非小细胞肺癌 PD-L1 表达和 CD8+淋巴细胞密度的影响

英文原题:The effect of neoadjuvant therapy on PD-L1 expression and CD8+lymphocyte density in non-small cell lung cancer.

查看英文原题

The effect of neoadjuvant therapy on PD-L1 expression and CD8+lymphocyte density in non-small cell lung cancer.

PubMed 2022/08/01(内容时间) Mod Pathol Q1 · IF 6.6(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

PD-L1表达是non-small cell lung cancer(NSCLC)中用于筛选接受免疫治疗患者的常规临床生物标志物。

然而,免疫治疗在可切除情况下的应用及最佳时机仍在研究中。我们旨在研究化疗对PD-L1表达和tumor infiltrating lymphocytes(TILs)的影响,目前对此仍知之甚少。

我们的回顾性、单中心新辅助队列包括2000-2016年间接受新辅助治疗后切除的96例连续NSCLC患者,其中包括53例配对的诊断时未接受化疗的标本。纳入了一个生物学匹配的114例初次切除手术队列。在全切片上评估PD-L1表达、CD8 + TILs密度和三级淋巴结构,并与临床病理特征和生存进行相关性分析。7/53例和12/53例在新辅助治疗后分别出现PD-L1表达降低和升高。大多数病例(n = 34)PD-L1表达无变化,其中大多数在两个样本中PD-L1 < 1%(21/34 [61.8%])。尽管与诊断活检相比,化疗后切除标本中CD8 + TILs密度显著更高(p = 0.031),但这可能是由于采样和统计偏倚所致。比较新辅助队列和手术队列时,未检测到PD-L1表达或CD8 + TILs密度的差异。在单变量分析中,较高的CD8 + TILs密度、较多的三级淋巴结构数量而非PD-L1表达与更长的生存显著相关。新辅助化疗后PD-L1表达升高与较短的5年生存无显著相关,但病例数非常少。在多变量分析中,仅pT分期和年龄仍为独立预后因素。

总之,与新辅助化疗前的诊断活检相比,PD-L1表达大多保持不变。PD-L1表达发生变化的病例样本量太小,无法就其任何预后价值得出结论。

展开英文摘要原文

PD-L1 expression is the routine clinical biomarker for the selection of patients to receive immunotherapy in non-small cell lung cancer (NSCLC).

However, the application and best timing of immunotherapy in the resectable setting is still under investigation.

We aimed to study the effect of chemotherapy on PD-L1 expression and tumor infiltrating lymphocytes (TILs), which is to date still poorly understood.

Our retrospective, single-centre neoadjuvant cohort comprised 96 consecutive patients with NSCLC resected 2000-2016 after neoadjuvant therapy, including paired diagnostic chemo-naïve specimens in 53 cases. A biologically matched surgical cohort of 114 primary resected cases was included. PD-L1 expression, CD8 + TILs density and tertiary lymphoid structures were assessed on whole slides and correlated with clinico-pathological characteristics and survival. Seven/53 and 12/53 cases had lower respectively higher PD-L1 expressions after neoadjuvant therapy. Most cases (n = 34) showed no changes in PD-L1 expression, the majority of these harboring PD-L1 < 1% in both samples (21/34 [61. 8%]). Although CD8 + TILs density was significantly higher after chemotherapy (p = 0. 031) in resections compared to diagnostic biopsies, this might be due to sampling and statistical bias.

No difference in PD-L1 expression or CD8 + TILs density was detected when comparing the neoadjuvant and surgical cohort. In univariable analyses, higher CD8 + TILs density, higher numbers of tertiary lymphoid structures but not PD-L1 expression were significantly associated with longer survival. Increased PD-L1 expression after neoadjuvant chemotherapy was not significantly associated with shorter 5-year survival, but the number of cases was very low.

In multivariable analysis, only pT category and age remained independent prognostic factors. In summary, PD-L1 expression was mostly unchanged after neoadjuvant chemotherapy compared to diagnostic biopsies. The sample size of cases with changed PD-L1 expression was too small to draw conclusions on any prognostic value.

论文信息

作者
Zens P、Bello C、Scherz A、von Gunten M、Ochsenbein A、Schmid RA、Berezowska S
第一作者单位
Institute of Pathology, University of Bern, Bern, Switzerland.Switzerland
通讯作者单位
Institute of Pathology, University of Bern, Bern, Switzerland. sabina.berezowska@chuv.ch.Switzerland
文献类型
非美国政府资助研究
期刊
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2022 Dec
原文标识
PubMed 35915139 · DOI 10.1038/s41379-022-01139-y